Hypertension, tachycardia, and reversible ardiomyopathy temporally associated with milnacipran use

Texas Heart Institute Journal

Volumn 38, Issue 6, 2011, Pages 714-718

  Forman, Mervyn B ^a   Sutej, Paul G ^b   Jackson, Edwin K ^c  

^a Saint Joseph's Hospital of Atlanta   (United States)

^b Arthritis and Rheumatology of Georgia   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressive agents; Cardiomyopathies diagnosis epidemiology etiology therapy; Catecholamines adverse effects; Fibromyalgia drug therapy; Hypertension chemically induced; Magnetic resonance angiography; Milnacipran; Myocardium pathology; Second generation administration Dosage adverse effects therapeutic use; Serotonin uptake inhibitors adverse effects therapeutic use; Takotsubo cardiomyopathy chemically induced; Treatment outcome; Ventricular dysfunction chemically induced

Indexed keywords

CARVEDILOL; CATECHOLAMINE; ENALAPRIL; HYDROXYCHLOROQUINE; MILNACIPRAN; PREDNISONE;

ADULT; ARTHRALGIA; ARTICLE; CARDIOMYOPATHY; CASE REPORT; CATECHOLAMINE BLOOD LEVEL; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBROMYALGIA; HUMAN; HYPERTENSION; RECOMMENDED DRUG DOSE; TACHYCARDIA; TREATMENT DURATION;

ADRENERGIC UPTAKE INHIBITORS; ADULT; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; CATECHOLAMINES; CORONARY ANGIOGRAPHY; CYCLOPROPANES; FEMALE; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; SEROTONIN UPTAKE INHIBITORS; TACHYCARDIA; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84858200373     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kassim TA, Clarke DD, Mai VQ, Clyde PW, Shakir KMM. Catecholamine-induced cardiomyopathy. Endocr Pract 2008; 14(9):1137-49.
2. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 2008;13(7 Suppl 11):27-33.
3. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. The efficacy and safety of milnacipran for treatment of f ibromyalgia. A randomized, doubleblind, placebo-controlled trial [published erratum appears in J Rheumatol 2009;36(3):661]. J Rheumatol 2009;36(2):398-409.
4. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15- week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial [published errata appear in Clin Ther 2009;31(2):446 and Clin Ther 2009;31(7):1617]. Clin Ther 2008;30(11):1988-2004.
5. de Toledo Ferraz Alves TC, Guerra de Andrade A. Hypertension induced by regular doses of milnacipran: a case report. Pharmacopsychiatry 2007;40(1):41-2.
6. Yoshida K, Higuchi H, Takahashi H, Shimizu T. Elevation of blood pressure induced by high-dose milnacipran. Hum Psychopharmacol 2002;17(8):431.
7. Periclou A, Palmer RH, Zheng H, Lindamood C 3rd. Effects of milnacipran on cardiac repolarization in healthy participants. J Clin Pharmacol 2010;50(4):422-33.
8. Caron J, Libersa C, Hazard JR, Lacroix D, Facq E, Guedon- Moreau L, et al. Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 1993;3(4):493-500.
9. Sutherland JA, Al Chekakie MO, Moran JF. Catecholamineinduced cardiomyopathy rapidly reversed with beta-blocker therapy. Congest Heart Fail 2009;15(4):193-5.
10. Budhwani N, Bonaparte KL, Cuyjet AB, Saric M. Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose. Rev Cardiovasc Med 2004;5(2):130-3.
11. Christoph M, Ebner B, Stolte D, Ibrahim K, Kolschmann S, Strasser RH, Schon S. Broken heart syndrome: Tako Tsubo cardiomyopathy associated with an overdose of the serotoninnorepinephrine reuptake inhibitor venlafaxine. Eur Neuropsychopharmacol 2010;20(8):594-7.
12. Selke KJ, Dhar G, Cohn JM. Takotsubo cardiomyopathy associated with titration of duloxetine. Tex Heart Inst J 2011;38 (5):573-6.
13. Doherty NE, Siegel RJ. Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1985;110(6):1257-65.
14. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus 2005;14(9):683-6.
15. Lundberg IE. Cardiac involvement in autoimmune myositis and mixed connective tissue disease. Lupus 2005;14(9):708-12.
16. Mosca M, Tani C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol 2007;21(6):1011-23.
17. Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P, et al. Undifferentiated connective tissue disease: a sevencenter cross-sectional study of 184 patients. Clin Rheumatol 2009;28(8):915-21.
18. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 2009;53(17):1475-87.
19. Ratliff NB, Estes ML, Myles JL, Shirey EK, McMahon JT. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med 1987;316(4):191-3.
20. Costedoat-Chalumeau N, Hulot JS, Amoura Z, Delcourt A, Maisonobe T, Dorent R, et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 2007;107(2):73-80.